HUTCHMED (HCM) said Thursday it earned a $20 million milestone payment from Takeda (TAK) triggered by reaching over $200 million in sales of metastatic colorectal cancer treatment fruquintinib.
Takeda, who holds exclusive global rights to the drug outside of mainland China, Hong Kong and Macau, generated $203 million in net sales of fruquintinib in nine months ended September 2024, the comany said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。